MergerMay 15, 2026, 06:17 AM
CRAC to Merge with Carvix; Reports Q1 Net Loss of $(263,493)
AI Summary
Crown Reserve Acquisition Corp. I (CRAC) announced a Business Combination Agreement with Carvix, Inc. on March 30, 2026, which will result in Carvix becoming a wholly-owned subsidiary of CRAC. Carvix stockholders are set to receive 50,000,001 shares at closing, with potential earnout shares up to 50,000,100 based on future performance targets. For the three months ended March 31, 2026, CRAC reported a net loss of $(263,493), while its Trust Account balance grew to $174,928,579. The company also disclosed substantial doubt about its ability to continue as a going concern if the business combination is not completed by the extended deadline of February 10, 2027.
Key Highlights
- Crown Reserve Acquisition Corp. I entered into a Business Combination Agreement with Carvix, Inc. on March 30, 2026.
- Carvix stockholders will receive 50,000,001 shares of common stock at closing, plus up to 50,000,100 earnout shares.
- The Sponsor may earn up to 3,000,000 additional shares based on annual milestones.
- Net loss for the three months ended March 31, 2026, was $(263,493).
- Cash and marketable securities in the Trust Account increased to $174,928,579 as of March 31, 2026.
- Warrant liability increased to $3,023,463 as of March 31, 2026, from $1,419,066 at December 31, 2025.
- Management identified substantial doubt about the company's ability to continue as a going concern.
- The deadline to complete a Business Combination is February 10, 2027.
Price Impact